Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
This mergerCounterparty日本予防医薬株式会社, 株式会社NRLファーマ
Disclosing companySoiken Holdings Inc.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
ラクトフェリンをはじめとする機能性素材の開発、販売及び技術供与等
Location Shinagawa Ward, TokyoShare capital 6,400万円Date of incorporation 1998 年 4 月 23 日
Consideration and expenses
Acquisition price株式その他の金銭等の交付はありません
Type of Consideration無償（株式その他の金銭等の交付なし）
Funding arrangementsNot applicable（株式その他の金銭等の交付なし）
Impact on Business Performance
The impact on the Company's consolidated results is expected to be immaterial.
Procedures and assumptions
Conditions Precedent to Execution合併契約承認株主総会（NRL、日本予防医薬）の承認（2026 年 3 月 31 日予定）
Management structure after acquisition合併後の存続会社である日本予防医薬の商号、所在地、代表者の役職・氏名、資本金、決算期に変更はなく、事業内容にNRLの事業内容が加わる。
| Item | Details |
|---|---|
| Transaction name | This merger |
| Counterparty name | 日本予防医薬株式会社, 株式会社NRLファーマ |
| Name of the Subject Company | 株式会社NRLファーマ（消滅会社） |
| Business Description of the Subject Company | ラクトフェリンをはじめとする機能性素材の開発、販売及び技術供与等 |
| Location of the Subject Company | Shinagawa Ward, Tokyo |
| Capital Stock of the Subject Company | 6,400万円 |
| Date of Establishment of the Subject Company | 1998 年 4 月 23 日 |
| Acquisition price | 株式その他の金銭等の交付はありません |
| Type of Consideration | 無償（株式その他の金銭等の交付なし） |
| Number of shares acquired | 取得なし（吸収合併によりNRLは解散） |
| Voting rights ownership percentage | Before 日本予防医薬：100%、NRL：99.93%（合併前の持株比率） (after not disclosed) |
| Funding arrangements | Not applicable（株式その他の金銭等の交付なし） |
| Impact on Business Performance | The impact on the Company's consolidated results is expected to be immaterial. |
| Date of board resolution | 2026 年 2 月 18 日 |
| Contract Date | 2026 年 2 月 18 日 |
| Execution Date / Effective Date | 1 April 2026 (scheduled) |
| Conditions Precedent to Execution | 合併契約承認株主総会（NRL、日本予防医薬）の承認（2026 年 3 月 31 日予定） |
| Management structure after acquisition | 合併後の存続会社である日本予防医薬の商号、所在地、代表者の役職・氏名、資本金、決算期に変更はなく、事業内容にNRLの事業内容が加わる。 |
Items this document does not state (14)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.事業ポートフォリオの最適化、機能性素材の開発機能とEC販売のノウハウ・販路・顧客基盤の一体化による業務プロセスおよび意思決定の迅速化、人的資本の統合による重複間接コストの削減、経営体制の効率化を目的としている。また、ユーザー基盤の集約や商品開発機能の効率化を通じて、総合ヘルスケアプラットフォームの機能・コンテンツの充実にもつなげるとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.